BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 31772325)

  • 1. FKBPL-based peptide, ALM201, targets angiogenesis and cancer stem cells in ovarian cancer.
    Annett S; Moore G; Short A; Marshall A; McCrudden C; Yakkundi A; Das S; McCluggage WG; Nelson L; Harley I; Moustafa N; Kennedy CJ; deFazio A; Brand A; Sharma R; Brennan D; O'Toole S; O'Leary J; Bates M; O'Riain C; O'Connor D; Furlong F; McCarthy H; Kissenpfennig A; McClements L; Robson T
    Br J Cancer; 2020 Feb; 122(3):361-371. PubMed ID: 31772325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer stem cells and breast cancer metastasis by downregulating DLL4 and Notch4.
    McClements L; Annett S; Yakkundi A; O'Rourke M; Valentine A; Moustafa N; Alqudah A; Simões BM; Furlong F; Short A; McIntosh SA; McCarthy HO; Clarke RB; Robson T
    BMC Cancer; 2019 Apr; 19(1):351. PubMed ID: 30975104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting treatment-resistant breast cancer stem cells with FKBPL and its peptide derivative, AD-01, via the CD44 pathway.
    McClements L; Yakkundi A; Papaspyropoulos A; Harrison H; Ablett MP; Jithesh PV; McKeen HD; Bennett R; Donley C; Kissenpfennig A; McIntosh S; McCarthy HO; O'Neill E; Clarke RB; Robson T
    Clin Cancer Res; 2013 Jul; 19(14):3881-93. PubMed ID: 23741069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FKBPL and peptide derivatives: novel biological agents that inhibit angiogenesis by a CD44-dependent mechanism.
    Valentine A; O'Rourke M; Yakkundi A; Worthington J; Hookham M; Bicknell R; McCarthy HO; McClelland K; McCallum L; Dyer H; McKeen H; Waugh DJ; Roberts J; McGregor J; Cotton G; James I; Harrison T; Hirst DG; Robson T
    Clin Cancer Res; 2011 Mar; 17(5):1044-56. PubMed ID: 21364036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The anti-migratory effects of FKBPL and its peptide derivative, AD-01: regulation of CD44 and the cytoskeletal pathway.
    Yakkundi A; McCallum L; O'Kane A; Dyer H; Worthington J; McKeen HD; McClements L; Elliott C; McCarthy HO; Hirst DG; Robson T
    PLoS One; 2013; 8(2):e55075. PubMed ID: 23457460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of A Novel Angiogenesis FKBPL-CD44 Pathway in Preeclampsia Risk Stratification and Mesenchymal Stem Cell Treatment.
    Todd N; McNally R; Alqudah A; Jerotic D; Suvakov S; Obradovic D; Hoch D; Hombrebueno JR; Campos GL; Watson CJ; Gojnic-Dugalic M; Simic TP; Krasnodembskaya A; Desoye G; Eastwood KA; Hunter AJ; Holmes VA; McCance DR; Young IS; Grieve DJ; Kenny LC; Garovic VD; Robson T; McClements L
    J Clin Endocrinol Metab; 2021 Jan; 106(1):26-41. PubMed ID: 32617576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anisomycin inhibits angiogenesis in ovarian cancer by attenuating the molecular sponge effect of the lncRNA‑Meg3/miR‑421/PDGFRA axis.
    Ye W; Ni Z; Yicheng S; Pan H; Huang Y; Xiong Y; Liu T
    Int J Oncol; 2019 Dec; 55(6):1296-1312. PubMed ID: 31638182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden.
    Abubaker K; Luwor RB; Zhu H; McNally O; Quinn MA; Burns CJ; Thompson EW; Findlay JK; Ahmed N
    BMC Cancer; 2014 May; 14():317. PubMed ID: 24886434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eradication of chemotherapy-resistant CD44+ human ovarian cancer stem cells in mice by intraperitoneal administration of Clostridium perfringens enterotoxin.
    Casagrande F; Cocco E; Bellone S; Richter CE; Bellone M; Todeschini P; Siegel E; Varughese J; Arin-Silasi D; Azodi M; Rutherford TJ; Pecorelli S; Schwartz PE; Santin AD
    Cancer; 2011 Dec; 117(24):5519-28. PubMed ID: 21692061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A rational approach for cancer stem-like cell isolation and characterization using CD44 and prominin-1(CD133) as selection markers.
    Lee YJ; Wu CC; Li JW; Ou CC; Hsu SC; Tseng HH; Kao MC; Liu JY
    Oncotarget; 2016 Nov; 7(48):78499-78515. PubMed ID: 27655682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gallbladder cancer-associated fibroblasts promote vasculogenic mimicry formation and tumor growth in gallbladder cancer via upregulating the expression of NOX4, a poor prognosis factor, through IL-6-JAK-STAT3 signal pathway.
    Pan MS; Wang H; Ansari KH; Li XP; Sun W; Fan YZ
    J Exp Clin Cancer Res; 2020 Nov; 39(1):234. PubMed ID: 33153467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ascites-derived ALDH+CD44+ tumour cell subsets endow stemness, metastasis and metabolic switch via PDK4-mediated STAT3/AKT/NF-κB/IL-8 signalling in ovarian cancer.
    Jiang YX; Siu MK; Wang JJ; Mo XT; Leung TH; Chan DW; Cheung AN; Ngan HY; Chan KK
    Br J Cancer; 2020 Jul; 123(2):275-287. PubMed ID: 32390009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metformin targets gastric cancer stem cells.
    Courtois S; Durán RV; Giraud J; Sifré E; Izotte J; Mégraud F; Lehours P; Varon C; Bessède E
    Eur J Cancer; 2017 Oct; 84():193-201. PubMed ID: 28822889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer.
    Lo CW; Chen MW; Hsiao M; Wang S; Chen CA; Hsiao SM; Chang JS; Lai TC; Rose-John S; Kuo ML; Wei LH
    Cancer Res; 2011 Jan; 71(2):424-34. PubMed ID: 21123455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival.
    Silva IA; Bai S; McLean K; Yang K; Griffith K; Thomas D; Ginestier C; Johnston C; Kueck A; Reynolds RK; Wicha MS; Buckanovich RJ
    Cancer Res; 2011 Jun; 71(11):3991-4001. PubMed ID: 21498635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FKBPL is a critical antiangiogenic regulator of developmental and pathological angiogenesis.
    Yakkundi A; Bennett R; Hernández-Negrete I; Delalande JM; Hanna M; Lyubomska O; Arthur K; Short A; McKeen H; Nelson L; McCrudden CM; McNally R; McClements L; McCarthy HO; Burns AJ; Bicknell R; Kissenpfennig A; Robson T
    Arterioscler Thromb Vasc Biol; 2015 Apr; 35(4):845-54. PubMed ID: 25767277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel model for evaluating therapies targeting human tumor vasculature and human cancer stem-like cells.
    Burgos-Ojeda D; McLean K; Bai S; Pulaski H; Gong Y; Silva I; Skorecki K; Tzukerman M; Buckanovich RJ
    Cancer Res; 2013 Jun; 73(12):3555-65. PubMed ID: 23576551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted activation of Stat3 in combination with paclitaxel results in increased apoptosis in epithelial ovarian cancer cells and a reduced tumour burden.
    Li H; Qian Y; Wang X; Pi R; Zhao X; Wei X
    Cell Prolif; 2020 Jan; 53(1):e12719. PubMed ID: 31778258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Angiogenesis: Taming the Medusa of Ovarian Cancer.
    Dhani NC; Oza AM
    Hematol Oncol Clin North Am; 2018 Dec; 32(6):1041-1055. PubMed ID: 30390759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitory effects of metformin at low concentration on epithelial-mesenchymal transition of CD44(+)CD117(+) ovarian cancer stem cells.
    Zhang R; Zhang P; Wang H; Hou D; Li W; Xiao G; Li C
    Stem Cell Res Ther; 2015 Dec; 6():262. PubMed ID: 26718286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.